A gene therapy called AMT-130 has shown positive results in a study on Huntington's disease, with some outlets reporting that it met its end points and significantly slowed the progression of the disease. However, there are conflicting reports about the therapy's path to regulatory approval, with some indicating an FDA submission is planned and others suggesting that the FDA may require additional data. The status of AMT-130's approval process is unclear, with reports of both potential hurdles and sustained clinical benefits.